Health & Fitness
Health and Fitness
Health and Fitness
Mon, April 18, 2011Sun, April 17, 2011Fri, April 15, 2011Thu, April 14, 2011Wed, April 13, 2011Tue, April 12, 2011Mon, April 11, 2011Sun, April 10, 2011Sat, April 9, 2011Fri, April 8, 2011Thu, April 7, 2011Wed, April 6, 2011Tue, April 5, 2011Mon, April 4, 2011Sun, April 3, 2011Sat, April 2, 2011Fri, April 1, 2011Thu, March 31, 2011Wed, March 30, 2011Tue, March 29, 2011RXi Pharmaceuticals to Webcast Presentation at BioCentury Future Leaders in the Biotech Industry Conference
Published in Health and Fitness on Friday, April 8th 2011 at 4:25 GMT by Market Wire
WORCESTER, Mass.--([ BUSINESS WIRE ])--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies, today announced that the Companya™s President and Chief Executive Officer, Mark J. Ahn, Ph.D., will present a corporate overview to include the companya™s recent announcement of their intent to acquire Apthera at BioCenturya™s Future Leaders Conference on Friday, April 15, 2011 at 9:00 a.m. ET, at the Millennium Broadway Hotel & Conference Center in New York City.
The acquisition provides RXi with a late stage product candidate, NeuVaxa", a peptide-based immunotherapy for low-to-intermediate HER2+ breast cancer, not eligible for Herceptin®, which is expected to enter Phase III clinical trials in the first half of 2012. The Companya™s first RNAi product, RXI-109 which targets CTGF (connective tissue growth factor) for anti-scarring, remains on track for an investigational new drug (IND) application filing this year.
A live webcast of the presentation will be available from the aInvestor Relationsa section of the Company's website, [ www.rxipharma.com ]. A replay of the presentation will be available for 30 days.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals is a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted and immunotherapy technologies. Based on the pioneering work of scientific founder and Nobel Laureate Dr. Craig Mello, RXia™s first RNAi product candidate, RXI-109 which targets CTGF (connective tissue growth factor), is scheduled to commence human clinical trials in anti-scarring in early 2012. RXi recently accelerated its product development focus with the acquisition of NeuVaxa" which is slated to commence Phase III clinical trials in low-to-intermediate HER2+ breast cancer patients, not eligible for Herceptin®, in the first half of 2012. For more information please visit us at [ www.rxipharma.com ]
